Wells Fargo Raises Kyverna Therapeutics (KYTX) PT to $27 on Confidence in KYV-101 Stiff Person Syndrome Trial Readout

Kyverna Therapeutics Inc. (NASDAQ:KYTX) is one of the best young stocks with huge upside potential. On October 8, Wells Fargo analyst Derek Archila raised the firm’s price target on Kyverna Therapeutics to $27 from $24, while maintaining an Overweight rating on the shares. Wells Fargo likes the risk/reward on KYV-101’s pivotal stiff person syndrome trial readout in H1 2026.

The firm believes that Wall Street underappreciates how de-risked the trial is. On September 24, Kyverna Therapeutics announced that updated data from Phase 1 investigator-initiated trials/IITs of its lead candidate, KYV-101, in progressive multiple sclerosis/MS would be presented at the 2025 European Committee for Treatment and Research in Multiple Sclerosis/ECTRIMS Congress in Barcelona, Spain.

Across both IITs, KYV-101 demonstrated a tolerable safety profile, consistent with observations from the first 100 patients treated with the therapy across all indications. Notably, there were no high-grade Cytokine Release Syndrome/CRS or Immune Effector Cell Associated Neurotoxicity Syndrome/ICANS events reported, and no serious adverse events/SAEs in the Stanford study.

KYV-101 is a fully human, autologous, CD19 CAR T-cell therapy with CD28 co-stimulation, currently being investigated for its potential to deliver deep B-cell depletion and immune system reset in various B-cell-driven autoimmune diseases

Kyverna Therapeutics Inc. (NASDAQ:KYTX) is a clinical-stage biopharmaceutical company that develops cell therapies for patients with autoimmune diseases.

While we acknowledge the potential of KYTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.